Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NVS vs ABBV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABBV Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ABBV Overall Winner 6-Pillar Tally: NVS 3 – 3 ABBV Matrix Metrics: NVS 3 – 7 ABBV

As of Nov 16, 2026, Abbvie Inc. (ABBV) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas ABBV carries 54.0/100 (HOLD) at $295.94 (18.2x Forward P/E, 36.6% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NVS vs ABBV
NVS NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap $302.9B
TTM Revenue $40.5B
Forward P/E 16.2x
Beta / 30D Vol 0.31β · 27% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 29.0 Fund 38.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.7% over 20 days), RSI 61
RSI-14: 60.8 · SMA20: $159.19 · SMA50: $149.17
ABBV NYSE Head-to-Head Winner
Abbvie Inc.
Pharmaceutical Preparations
$295.94
+0.31% 1D
Market Cap $520.5B
TTM Revenue $66.0B
Forward P/E 18.2x
Beta / 30D Vol -0.03β · 20% Vol
Unified Composite Score
54.0 / 100 HOLD
Tech 34.0 Fund 50.0 Flow 72.0 Mom 46.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.0% over 20 days), RSI 65
RSI-14: 64.9 · SMA20: $290.38 · SMA50: $276.32

6-Pillar Scorecard Institutional Category Breakdown (NVS 3 – 3 ABBV)

Columns: Metric · NVS · ABBV
1. Valuation Multiples NVS
Forward P/E 16.2x 18.2x
Trailing P/E 30.6x 50.6x
PEG Ratio 3.81x 0.59x
EV / Revenue 7.5x 8.9x
2. Growth & Scale ABBV
Revenue Growth (YoY) +4.7% +10.3%
Earnings Growth (YoY) -68.8% N/A
TTM Revenue (USD) $40.5B $66.0B
Market Cap $302.9B $520.5B
3. Profitability & Quality ABBV
Gross Margin 75.2% 73.7%
Operating Margin 34.0% 36.6%
Net Profit Margin 17.5% 15.7%
Return on Equity (ROE) 24.3% 62.3%
4. Balance Sheet & Cash Flow NVS
Cash Generation (TTM) $17.0B EBITDA $18.9B
Cash Flow Margin 42.0% EBITDA Mgn 28.6%
Net Cash / Leverage $19.71 Book/Sh · 24.3% ROE $70.1B Net Debt
Dividend Yield 2.96% 2.35%
5. Options & Positioning ABBV
Options Structure Phase UNCLASSIFIED BREAKOUT
Current IV / %ile 16.9% (6th %ile) 23.1% (12th %ile)
Put/Call OI Skew Thin ADR Chain 0.43x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat NVS
OpEx & R&D Intensity 41.2% of Rev ($16.7B) 37.1% of Rev ($24.5B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - General Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NVS (3) vs ABBV (7)
Institutional Metric NVS ABBV Criterion Row Edge
Market Capitalization
Scale
$302.9B $520.5B Larger Scale ABBV
Trailing P/E Ratio
Valuation
30.6x 50.6x Lower Multiple NVS
Forward P/E Ratio
Valuation
16.2x 18.2x Lower Multiple NVS
Revenue Growth (YoY)
Growth
+4.7% +10.3% Higher Growth ABBV
Operating Margin (TTM)
Profitability
34.0% 36.6% Higher Margin ABBV
Net Profit Margin
Profitability
17.5% 15.7% Higher Margin NVS
Return on Equity (ROE)
Capital Efficiency
24.3% 62.3% Higher ROE ABBV
52-Week Range Position
Momentum
81% ($123–$170) 94% ($191–$303) Stronger Trend ABBV
Beta / 30D Volatility
Risk Regime
0.31β · 27% Vol -0.03β · 20% Vol Lower Realized Risk ABBV
Unified Institutional Score
Composite Signal
41.5 / 100 (SELL) 54.0 / 100 (HOLD) Higher Composite ABBV
Trailing 12M Revenue (USD)
Operating Scale
$40.5B $66.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.2% 73.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.81x PEG · 7.5x EV/Rev 0.59x PEG · 8.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$17.0B EBITDA ($19.71 Book/Sh · 24.3% ROE) $18.9B ($70.1B Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NVS +3.59 pp
NVS: +7.28% · ABBV: +3.69%
3M Horizon ABBV +9.74 pp
NVS: +4.56% · ABBV: +14.3%
6M Horizon ABBV +32.98 pp
NVS: +8.34% · ABBV: +41.32%
1Y Horizon ABBV +4.9 pp
NVS: +22.5% · ABBV: +27.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs ABBV. Trailing 12-month operating profitability (NVS 34.0% vs ABBV 36.6%) and valuation multiples (NVS 16.2x vs ABBV 18.2x Forward P/E) are benchmarked directly in Pillar 4 below.

NVS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40.5B
Gross Margin75.2%
Op. Margin34.0%
ROE / Fwd P/E24.3% · 16.2x
ABBV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$66.0B
Gross Margin73.7%
Op. Margin36.6%
ROE / Fwd P/E62.3% · 18.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NVS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 16.9%
IV Percentile 6th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NVS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABBV BREAKOUT
94d in phase · OBV ACCUMULATION
Current IV 23.1%
IV Percentile 12th %ile
Put/Call OI Skew 0.43x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ABBV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NVS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $302.9B market capitalization and 34.0% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($16.7B)
90D Engineering Disclosures 0 Published
ABBV Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $520.5B market capitalization and 36.6% operating margin.
OpEx & R&D Reinvestment 37.1% of Rev ($24.5B)
90D Engineering Disclosures 0 Published

Investor FAQ NVS vs ABBV Key Questions & Quantitative Answers

As of Nov 16, 2026, Abbvie Inc. (ABBV) is the stronger overall head-to-head candidate over Novartis AG (NVS) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). NVS carries a Unified Composite Score of 41.5/100 (SELL) at $161.59 (16.2x Forward P/E, 34.0% operating margin), whereas ABBV carries 54.0/100 (HOLD) at $295.94 (18.2x Forward P/E, 36.6% operating margin). Technically, NVS sits in a Markup phase (RSI 60.8, UNCLASSIFIED options structure) and ABBV sits in a Markup phase (RSI 64.9, BREAKOUT options structure).

ABBV leads the Growth & Scale pillar: NVS posts +4.7% YoY revenue growth and -68.8% YoY earnings growth on $40.5B TTM revenue (75.2% gross margin, 34.0% operating margin), compared with ABBV at +10.3% YoY revenue growth and N/A YoY earnings growth on $66.0B TTM revenue (73.7% gross margin, 36.6% operating margin). On trailing 12-month operating scale, NVS generates $40.5B in USD-normalized revenue versus $66.0B for ABBV. In operating R&D and SG&A reinvestment, NVS deploys 41.2% of Rev ($16.7B) (0 90-day corporate R&D disclosures) versus 37.1% of Rev ($24.5B) (0 disclosures) for ABBV.

NVS screens cheaper on headline valuation multiples. NVS trades at 16.2x Forward P/E, 30.6x Trailing P/E, 3.81x PEG, and 7.5x EV/Revenue (42.0% EBITDA margin), whereas ABBV trades at 18.2x Forward P/E, 50.6x Trailing P/E, 0.59x PEG, and 8.9x EV/Revenue (28.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NVS (24.3% ROE) versus ABBV (62.3% ROE) capital efficiency.

In options market volatility and institutional positioning, NVS carries 16.9% implied volatility (6th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.31β · 27% Vol realized risk). By comparison, ABBV carries 23.1% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.43x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (-0.03β · 20% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.